Twenty-two percent of the participants aged 75 years or older had MCI. 2 key findings →
Participants: 927 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Research
27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Patients with mild cognitive impairment (MCI) showed a high probability to be diagnosed with Alzheimer dementia (AD) after 30 months. 1 key finding →
Participants: 1,505 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This simple and feasible cognitive impairment prediction model could identify community-dwelling elderly people at the greatest 3-year risk for cognitive impairment, which could help community nurses in the early identification of dementia. 1 key finding →
Design: prospective cohort Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The dementia population is increasing as the world's population is growing older. 1 key finding →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
There were insufficient data to make any recommendations regarding cognitive screening of asymptomatic individuals. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Women with MCI have greater longitudinal rates of cognitive and functional progression than men. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The predictive validity of mild cognitive impairment (MCI) for identifying future Alzheimer disease (AD) cases is improved in the presence of anxiety symptoms. 1 key finding →
Participants: 185 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Our findings support the association of increased neuroinflammation during the progression of MCI and AD, relative to HCs. 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The NIA-AA criteria apply to most MCI subjects in both the community and clinical trials settings; however, a sizeable proportion of subjects had conflicting biomarkers, which may be very important and need to be explored. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
60/100
MBI and SCD together were associated with the greatest risk of decline. 4 key findings →
Participants: 2,769 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
60/100
The models could aid clinicians in the interpretation of CSF biomarker and hippocampal volume results in individuals with MCI, and help research and clinical settings to prepare for a future of precision medicine in Alzheimer's disease. 1 key finding →
Participants: 883 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The Mini-Mental State Examination (MMSE) is recommended to test for cognitive impairment and to monitor medication response. 4 key findings →
Design: randomized controlled trial Participants: 7,073 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Many people with mild cognitive impairment (MCI) suffer from concomitant depression or anxiety. 4 key findings →
Design: cross-sectional Participants: 4,168 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The temporal relationship of cognitive deficit and functional impairment in Alzheimer's disease (AD) is not well characterized. 4 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The relationship between mild behavioral impairment (MBI) and Alzheimer's disease (AD) is intricate and still not well investigated. 4 key findings →
Design: longitudinal study Participants: 1,129 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 844 eligible individuals were consecutively approached, 294 consented to participate, and 204 completed the study (mean [SD] age, 70.0 [5.1] years; 127 women [62.3%]). 5 key findings →
Design: cross-sectional Participants: 127 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Persons with MCI also have impaired motor function, and the degree of impairment in lower extremity function is related to the risk of AD. 1 key finding →
Design: cohort study Participants: 558 Evidence: moderate
Full summary, score breakdown and related studies → Original source
59/100
International hospital-based studies have indicated a high risk of cognitive impairment after stroke, evidence from community-based studies in China is scarce. 2 key findings →
Design: cross-sectional Participants: 599 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Changes to everyday spoken language ("connected language") are evident in persons with AD dementia, yet little is known about when these changes are first detectable on the continuum of cognitive decline. 2 key findings →
Design: longitudinal study Participants: 264 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
DCR outperforms the MMSE in detecting and classifying cognitive impairment-in a fraction of the time-while being not influenced by a patient's ethnicity. 5 key findings →
Participants: 360 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Men and women have different risk profiles for both MCI and progression to dementia. 1 key finding →
Participants: 6,892 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
59/100
Early PD-MCI, regardless of persistence or reversion to normal cognition, has prognostic value for predicting dementia in patients with PD. 2 key findings →
Participants: 178 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cognitive changes in normal individuals who will subsequently decline may be observed at least 6.5 years prior to symptom onset. 1 key finding →
Design: longitudinal study Participants: 208 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Long-term SSRI treatment may delay progression from MCI to Alzheimer's dementia. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Age and gender were observed to be associated with MCI, in which age was considered as an impact factor for DR. The strong heterogeneity may result from variations in study design and baselines. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
From across this tag
10 of the 846 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Progression of mild cognitive impairment to dementia: a challenge to current thinking
- Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment
- Sparse learning and stability selection for predicting MCI to AD conversion using baseline ADNI data
- Multimodal magnetic resonance imaging analysis of early mild cognitive impairment
- The Differentiation of Amnestic Type MCI from the Non-Amnestic Types by Structural MRI
- Social and socioeconomic factors and cognitive outcomes in multiple sclerosis
- Measurement differences in the Harmonized Cognitive Assessment Protocol across ethnicity and language in the United States
- Diabetic retinopathy as the primary predictor of mild cognitive impairment in type 2 diabetes: Insights from machine learning models
- Age- and Sex-Specific Prevalence and Modifiable Risk Factors of Mild Cognitive Impairment Among Older Adults in China: A Population-Based Observational Study
- Improving identification of cognitive impairment in primary care
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →